Back to News
Market Impact: 0.1
Candel Therapeutics Adds Regulatory Executive Martine Zimmermann To Board As BLA Filing Nears
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Candel Therapeutics appointed Martine Zimmermann, PharmD, to its board of directors effective September 8, 2026. The clinical-stage immunotherapy company's announcement is a routine governance update with limited expected near-term valuation impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
CADL0.20
More News
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- HSBC reports third-quarter pretax profit in line with estimates on net income boost
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Microsoft offers to buy out a quarter of its workforce
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Meta Announces Pricing of Offering of Depositary Shares Representing Series A Mandatory Convertible Preferred Stock and Offering of Class A Common Stock in Connection with Forward Sale Agreements